Literature DB >> 16298217

Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study.

Joel G Ray1, Marian J Vermeulen, Michael J Schull, Donald A Redelmeier.   

Abstract

BACKGROUND: Maternal placental syndromes, including the hypertensive disorders of pregnancy and abruption or infarction of the placenta, probably originate from diseased placental vessels. The syndromes arise most often in women who have metabolic risk factors for cardiovascular disease, including obesity, pre-pregnancy hypertension, diabetes mellitus, and dyslipidaemia. Our aim was to assess the risk of premature vascular disease in women who had had a pregnancy affected by maternal placental syndromes.
METHODS: We did a population-based retrospective cohort study in Ontario, Canada, of 1.03 million women who were free from cardiovascular disease before their first documented delivery. We defined the following as maternal placental syndromes: pre-eclampsia, gestational hypertension, placental abruption, and placental infarction. Our primary endpoint was a composite of cardiovascular disease, defined as hospital admission or revascularisation for coronary artery, cerebrovascular, or peripheral artery disease at least 90 days after the delivery discharge date.
FINDINGS: The mean (SD) age of participants was 28.2 (5.5) years at the index delivery, and 75 380 (7%) women were diagnosed with a maternal placental syndrome. The incidence of cardiovascular disease was 500 per million person-years in women who had had a maternal placental syndrome compared with 200 per million in women who had not (adjusted hazard ratio [HR] 2.0, 95 CI 1.7-2.2). This risk was higher in the combined presence of a maternal placental syndrome and poor fetal growth (3.1, 2.2-4.5) or a maternal placental syndrome and intrauterine fetal death (4.4, 2.4-7.9), relative to neither.
INTERPRETATION: The risk of premature cardiovascular disease is higher after a maternal placental syndrome, especially in the presence of fetal compromise. Affected women should have their blood pressure and weight assessed about 6 months postpartum, and a healthy lifestyle should be emphasised.

Entities:  

Mesh:

Year:  2005        PMID: 16298217     DOI: 10.1016/S0140-6736(05)67726-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  218 in total

Review 1.  Molecular Mechanisms of Preeclampsia.

Authors:  Tammy Hod; Ana Sofia Cerdeira; S Ananth Karumanchi
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-20       Impact factor: 6.915

2.  The relationship of a family history for hypertension, myocardial infarction, or stroke with cardiovascular physiology in young women.

Authors:  Carole A McBride; Sarah A Hale; Meenakumari Subramanian; Gary J Badger; Ira M Bernstein
Journal:  Reprod Sci       Date:  2013-09-10       Impact factor: 3.060

3.  Primary Prevention of Atherosclerotic Cardiovascular Disease in Women.

Authors:  Rebeccah A McKibben; Mahmoud Al Rifai; Lena M Mathews; Erin D Michos
Journal:  Curr Cardiovasc Risk Rep       Date:  2015-12-29

4.  Pre-eclampsia and increased cardiovascular risk.

Authors:  L A Magee; P von Dadelszen
Journal:  BMJ       Date:  2007-11-01

Review 5.  The Use of Sex-Specific Factors in the Assessment of Women's Cardiovascular Risk.

Authors:  Anandita Agarwala; Erin D Michos; Zainab Samad; Christie M Ballantyne; Salim S Virani
Journal:  Circulation       Date:  2020-02-17       Impact factor: 29.690

Review 6.  Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA risk assessment guidelines.

Authors:  Nivee P Amin; Seth S Martin; Michael J Blaha; Khurram Nasir; Roger S Blumenthal; Erin D Michos
Journal:  J Am Coll Cardiol       Date:  2014-05-07       Impact factor: 24.094

Review 7.  Report of the National Heart, Lung, and Blood Institute Working Group on Hypertension: Barriers to Translation.

Authors:  Curt D Sigmund; Robert M Carey; Lawrence J Appel; Donna K Arnett; Hayden B Bosworth; William C Cushman; Zorina S Galis; Melissa Green Parker; John E Hall; David G Harrison; Alicia A McDonough; Holly L Nicastro; Suzanne Oparil; John W Osborn; Mohan K Raizada; Jacqueline D Wright; Young S Oh
Journal:  Hypertension       Date:  2020-02-17       Impact factor: 10.190

8.  Epworth sleepiness scale scores and adverse pregnancy outcomes.

Authors:  Ghada Bourjeily; Rana El Sabbagh; Peter Sawan; Christina Raker; Carren Wang; Beth Hott; Mariam Louis
Journal:  Sleep Breath       Date:  2013-02-19       Impact factor: 2.816

9.  Cardiovascular Disease in Women Across the Lifespan: The Importance of Sleep.

Authors:  Stacie L Daugherty; Jason R Carter; Ghada Bourjeily
Journal:  J Womens Health (Larchmt)       Date:  2020-02-25       Impact factor: 2.681

10.  Elevated lipoprotein(a) levels and homozygous human platelet antigen 1b (HPA-1b) genotype are risk factors for intrauterine growth restriction (IUGR).

Authors:  Andrea Gerhardt; Nadja Howe; Jan Steffen Krüssel; Ruediger Eberhard Scharf; Rainer Bernd Zotz
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.